Navigation Links
CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS
Date:9/9/2009

TITUSVILLE, N.J., Sept. 9 /PRNewswire/ -- Attention Deficit Hyperactivity Disorder (ADHD) is estimated to impact up to 20 percent of children(1) and 4 percent of adults in the U.S.(2) Recent studies suggest ADHD is underdiagnosed: researchers estimate up to 20 percent of U.S. school-aged children meet the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria, but only 7.8 percent report receiving an ADHD diagnosis.(3) Meanwhile, it is estimated that just 15 percent of U.S. adults with ADHD have been diagnosed with the condition.(2)

To help elevate understanding of this condition, in the past several years the U.S. ADHD community has targeted September as a month of national recognition for ADHD awareness. In anticipation, McNeil Pediatrics(TM), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. and makers of CONCERTA((R)) (methylphenidate HCI), approved for treatment of ADHD in children and adults, is providing an innovative resource for information on ADHD and treatment: the CONCERTA((R)) Mobile Web.

By texting "ADHD" to 87415 on any mobile device -- such as a cell phone, smartphone, personal digital assistant (PDA) or handheld computer -- consumers can access the CONCERTA((R)) Mobile Web. The resource includes background on ADHD in children and adults, an interactive symptom screener from the World Health Organization (WHO), video testimonials from families impacted by ADHD, information on CONCERTA((R)) treatment as well as a CONCERTA((R)) coupon offer. The CONCERTA((R)) Mobile Web also offers one-click convenience to speak with trained professionals about general ADHD and treatment questions at the CONCERTA((R)) ADHD Support Center (also available by calling 1-877-324-ADHD).

This new resource is timely, given that according to a recent comScore, Inc. report, the number of people in the U.S. using their mobile device to access news and inform
'/>"/>

SOURCE McNeil Pediatrics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. District Court Decision Received in CONCERTA(R) Patent Case
2. Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA(R) (methylphenidate transdermal system) patches announced
3. Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever
4. ICC Launches New Elpac Brand Convection Cooled 100-Watt Open Frame Power Supply
5. Bounty Parenting Club Launches View on Demand How to Breastfeed Video
6. Founder of Curidium Launches Elixior, an Advisory Company Focused on the Development and Growth of Innovative Personalized Medicine Businesses
7. Fairfield, New Jersey Cosmetic Dentistry Practice Launches State-of-the-art New Website
8. National Alliance on Mental Illness (NAMI Michigan) Launches TV Awareness Campaign
9. PRC Launches New Web Resource for Teaching Language to Children & Adults with Speech Disabilities
10. Rochester Medical Launches StrataSI(TM) & StrataNF(TM) Next Generation Foley Catheters
11. RBC Life Sciences Launches New Initiatives Aimed at Building Its Network Marketing Business Across North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... The Global Allopurinol Industry Report 2015 ... current state of the Allopurinol industry.With 147 tables ... the state of the industry and is a ... and individuals interested in the market. The report ... definitions, classifications, applications and industry chain structure. The ...
(Date:5/29/2015)... Designed with the versatile athlete in ... an all new, exclusive line of supplementation called The ... latest and greatest, high impact, result driven ingredients that ... The 24/7 Series can be used by anyone from ... casual fitness enthusiasts. There are no stimulant based ingredients ...
(Date:5/29/2015)... VA (PRWEB) May 29, 2015 Javlin ... a new U.S. headquarters and a larger team, with ... and increase CloverETL's market share in the U.S. and ... the Javlin Group, achieved significant growth in 2014 with ... of Javlin’s premier data integration platform, CloverETL. To accelerate ...
(Date:5/29/2015)... This is a professional and ... Naproxen industry.The report provides a basic overview of ... chain structure. The Naproxen market analysis ... trends, competitive landscape analysis, and key regions development ... as manufacturing processes and cost structures are also ...
(Date:5/29/2015)... Michigan (PRWEB) May 29, 2015 Vulvodynia ... and can cause significant physical, sexual, and psychological distress. ... altering disorder of Vulvodynia. The actual diagnosis is often ... in Endometriosis, they realize that this problem can be ... experiencing any of these symptoms, they need to schedule ...
Breaking Medicine News(10 mins):Health News:Allopurinol Industry (Global, China) 2015 Research Analysis and 2020 Forecasts 2Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 2Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 3Health News:Growth of Data Integration Platform CloverETL Continues in North America 2Health News:Naproxen Market Analysis For Global & China Regions 2020 Research Forecasts 2
... of parents have used cough medicine for children younger ... nor proven effective for children in this age group, ... of Melbourne and Royal Childrens Hospital study, surveyed 325 ... and child care centres about their use of over-the-counter ...
... Washington, DC (Thursday, May 15, 2008) An often ... an increased risk of death for patients on kidney ... the June 2008 issue of the Journal of the ... clinical indicator beyond well-known risk factors for cardiovascular mortality ...
... 2008 Physicians and dentists should collaborate to improve ... may develop osteoporosis, say researchers in the cover story ... American Dental Association. , The authors of the article, ... medical and dental literature to examine osteoporosis effect on ...
... Presentation will be Web cast live, LAVAL, ... (NASDAQ:,BLUS; TSX: BLU, formerly known as Neurochem Inc.) ... Francesco Bellini, BELLUS Health,s Chairman,President and Chief Executive ... and Renshaw 5th Annual Global Healthcare Conference to ...
... revenues for the quarter decrease approximately 3% vs. ... Medical Corporation,(OTC Bulletin Board: CONX), a worldwide developer ... third quarter Form 10-QSB and,reported financial results. The ... have advanced during the quarter and nine months,ended ...
... Systems,(TSX:LMZ), a healthcare technology company and developer of ... announced that it has,entered into an agreement with ... to license CALM Shoulder Screen. Regional is one,of ... New Jersey,serving over 200,000 women annually and delivering ...
Cached Medicine News:Health News:Study finds parents use cough medicines on under-2s despite the warnings 2Health News:Hidden heart condition increases the risk of death in patients waiting for kidney transplants 2Health News:BELLUS Health to present at the Rodman and Renshaw 5th Annual Global Healthcare Conference 2Health News:Corgenix Reports Third Quarter Fiscal 2008 Financial Results 2Health News:Corgenix Reports Third Quarter Fiscal 2008 Financial Results 3Health News:Corgenix Reports Third Quarter Fiscal 2008 Financial Results 4Health News:LMS CALM Shoulder Screen(TM) selected by New Jersey physician group to minimize obstetrical risks 2Health News:LMS CALM Shoulder Screen(TM) selected by New Jersey physician group to minimize obstetrical risks 3
(Date:5/29/2015)... MENLO PARK, Calif. , May ... (OTCQX: DMPI) ("DelMar" and the "Company"), a ... cancer therapies in new orphan drug indications, presented ... of Cancer Research (AACR) Advances in Brain Cancer ... lead product candidate VAL-083 (dianhydrogalactitol) to ...
(Date:5/29/2015)... 29, 2015 Amgen (NASDAQ: AMGN ... Phase 3, global, randomized, placebo-controlled trials evaluating AMG ... secondary hyperparathyroidism (SHPT) in patients with chronic kidney ... primary endpoint, demonstrating that a greater proportion of ... greater than 30 percent reduction in parathyroid hormone ...
(Date:5/28/2015)... and Company (NYSE: LLY ) announced today the pricing ... to $1.6 billion aggregate principal amount of certain of its ... and did not validly withdraw, their notes on or before ... on May 27, 2015 (the early tender date), and which ... the total consideration. The total consideration for each series of ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
... PITTSBURGH, Dec. 16 Cohera Medical Inc. today announced ... of its lead surgical adhesive product, TissuGlu®. Initiation of ... progression of the lead product toward clinical practice. ... study to investigate the safety of TissuGlu and its ...
... , , INDIANAPOLIS, Dec. 16 RealMed has been ranked ... Top 20 Best in KLAS Awards: Software & Professional Services ... providing advanced, online, automated transactions processing between healthcare providers and ... specializing in vendor performance measurement in the software, professional services, ...
Cached Medicine Technology:First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 2First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 3RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3
Claes Shielded Retinotomy Scissors, Vertical...
Indirect hemagglutination assay (IHA) for the detection and semi-quantitation of human antibodies to the bacteria of the genus Leptospira. Each kit contains test cells, control cells, and positive an...
... antibody (IFA) test for ... of human serum IgG ... capsid antigen (VCA). Each ... slides, FITC IgG conjugate, ...
... (IFA) test for the detection and ... to the detection and semi-quantitation of ... early antigens, both restricted (R) and ... 12-well slides, FITC conjugate, positive and ...
Medicine Products: